Patient characteristics
| Sucessfully biopsied patients, N = 948 (%) | Matched treatment population, N = 199 (%) | |
|---|---|---|
| Age at inclusion | ||
| N | 948 | 199 |
| Median | 57 | 57 |
| Range | 19–86 | 28–86 |
| Sex | ||
| Male | 485 (51%) | 85 (43%) |
| Female | 463 (49%) | 114 (57%) |
| ECOG performance status | ||
| 0 | 348 (46%) | 88 (50%) |
| 1 | 396 (52%) | 86 (49%) |
| 2 | 13 (2%) | 3 (2%) |
| Missing | 191 | 22 |
| Tumor type | ||
| Head and neck | 111 (12%) | 15 (8%) |
| Digestive | 197 (21%) | 46 (23%) |
| Lung | 170 (18%) | 32 (16%) |
| Bone | 11 (1%) | 0 (0%) |
| Melanoma | 12 (1%) | 3 (2%) |
| Mesothelioma and soft tissue | 26 (3%) | 4 (2%) |
| Breast | 135 (14%) | 38 (19%) |
| Gynecological, female | 83 (9%) | 24 (12%) |
| Urological | 158 (16%) | 29 (15%) |
| Central nervous system | 1 (0%) | 0 (0%) |
| Thyroid and other endocrine glands | 8 (1%) | 2 (1%) |
| Ill-defined primary tumor | 36 (4%) | 6 (3%) |
| Metastasis at inclusion | ||
| No (locally advanced) | 60 (6%) | 7 (4%) |
| Yes | 887 (94%) | 192 (96%) |
| Missing | 1 | 0 |
| Number of metastatic sites | ||
| Median | 2 | 2 |
| Range | 0–9 | 0–9 |
| Missing | 1 | 0 |
| Number of previous therapies for advanced disease | ||
| Median | 4 | 4 |
| Range | 0–15 | 1–14 |
| Missing | 19 | 0 |
| RMH prognostic score | ||
| N | 907 | 194 |
| Median | 1 | 1 |
| Range | 0–3 | 0–3 |
| Missing | 41 | 5 |